AzaC treatment of mice that underwent a transplantation with delayed allogeneic T cells mitigates GVHD. (A) Schema of the experiments. B6 mice (CD45.2) TCD BM (5 × 106 cells) were used as a stem cell source. To induce GVHD, 2 × 106 Tconv (B6, CD45.1) were given on day 11 after SCT followed by the treatment with AzaC/Dec/PBS (every other day; 4 doses) starting on day 15 after SCT. (B-F) Mice treated with AzaC (2 mg/kg) show significantly higher survival rate (B), less weight loss (C), and more B cells (E) and T cells (F) with donor engraftment (D) than mice infused with pbsTs. (G) AzaC group also show increased Treg population in peripheral blood. T rec: T cells from recipient; T BM: T cells from donor BM; T donT: T cells from donor T cells; B BM: B cells from donor BM. (D-G) Analyzed 1 month after transplantation. A pool of 4 independent experiments.
